|
BUYINS.NET: HTE, TRX, AGIX, OPTR, GLOB, AMPXQ Have Been On BUYINS.NET
Naked Short List For 13 Consecutive Trading Days
(M2 PressWIRE Via Acquire Media NewsEdge)
RDATE:29092008
BUYINS.NET, www.buyins.net, announced today that these select companies
have been on the NASDAQ, AMEX and NYSE naked short threshold list for
13 consecutive trading days: Harvest Energy Trust Trust Units (NYSE:
HTE), Tronox Inc. (NYSE: TRX), AtheroGenics Inc. (NASDAQ: AGIX),
Optimer Pharmaceuticals Inc. (NASDAQ: OPTR), Global Med Technologies
Inc. (OTCBB: GLOB), Ampex Corp. (OTC: AMPXQ). For a complete list of
companies on the naked short list please visit our web site. To find
the SqueezeTrigger Price before a short squeeze starts in any stock, go
to www.buyins.net.
Regulation SHO took effect January 3, 2005, and provides a new
regulatory framework governing short selling of securities. It was
designed with the objective of simplifying and modernizing short sale
regulation and providing controls where they are most needed. At the
conclusion of each settlement day, data is provided on securities in
which: 1) there are at least 10,000 shares in aggregate failed
deliveries for the security for five consecutive settlement days, and
2) these failures constitute at least 0.5% of the issuer's total shares
outstanding. Regulation SHO mandates that, if a clearing agent has had
a fail-to-deliver position for 13 consecutive settlement days, that
clearing agent, and the broker/dealer it clears for, must purchase
securities to close out its fail to deliver position.
Harvest Energy Trust Trust Units (NYSE: HTE) operates as an open-ended
investment trust in Canada. It engages in the exploitation and
development of petroleum and natural gas properties in western Canada.
The company also conducts petroleum refining and marketing operations
in the Province of Newfoundland and Labrador. As of December 31, 2007,
it had net total proved plus probable reserves of approximately 192,297
million barrels of oil equivalent. The company was founded in 2002 and
is headquartered in Calgary, Canada. With 152.73 million shares
outstanding and 1.51 million shares declared short as of September
2008, the failure to deliver in shares of HTE has not been resolved and
a buy-in is imminent. According to quarterly data provided by the SEC,
there were still 839,441 shares of HTE that were failing-to-deliver as
of November 22, 2006.
Tronox Inc. (NYSE: TRX) produces and markets titanium dioxide pigment
in the United States and internationally. The company's titanium
dioxide, a white pigment is used in a range of products for its ability
to impart whiteness, brightness, and opacity. Its pigment product is
used in coatings, plastics, and paper, as well as various specialty
products, such as inks, food, and cosmetics. The company also offers
electrolytic manganese dioxide, which is used as active cathode
material for alkaline batteries; lithium manganese dioxide that is used
as rechargeable battery material; sodium chlorate for the pulp and
paper industry; boron trichloride, a specialty chemical gas, which is
used in various products, including pharmaceuticals, semiconductors,
high-performance fibers, specialty ceramics, and epoxies; and elemental
boron that is used in igniter formulations for defense, pyrotechnic,
and air bag industries. Tronox Incorporated was founded in 1964 and is
based in Oklahoma City, Oklahoma. Tronox Inc. (NYSE:TRX) operates
independently of Kerr-McGee Corp. as of March 30, 2006. With 41.68
million shares outstanding and 2.91 million shares declared short as of
September 2008, the failure to deliver in shares of TRX has not been
resolved and a buy-in is imminent. According to quarterly data provided
by the SEC, there were still 1,290,033 shares of TRX that were
failing-to-deliver as of November 28, 2005.
AtheroGenics Inc. (NASDAQ: AGIX) a research-based pharmaceutical
company, focuses on the discovery, development, and commercialization
of drugs for the treatment of chronic inflammatory diseases, including
diabetes and coronary heart disease. The company's V-Protectant
technology based products include AGI-1067, a phase III clinical trial
product for the treatment of type 2 diabetes and atherosclerosis;
AGI-1096, a phase I clinical trial antioxidant and selective
anti-inflammatory agent for the treatment of transplant rejection; and
other V-Protectant compounds for the treatment of cardiovascular and
inflammatory disease. AtheroGenics has collaboration with Astellas
Pharma, Inc. to develop AGI-1096 as an oral treatment for the
prevention of organ transplant rejection. The company was founded in
1993 and is based in Alpharetta, Georgia. On September 15, 2008, an
involuntary petition for liquidation under Chapter 7 was filed against
AtheroGenics, Inc in the US Bankruptcy Court for the Northern District
of Georgia, Atlanta. With 39.52 million shares outstanding and 7.48
million shares declared short as of September 2008, the failure to
deliver in shares of AGIX has not been resolved and a buy-in is
imminent. According to quarterly data provided by the SEC, there were
still 12,102,225 shares of AGIX that were failing-to-deliver as of
March 30, 2007.
Optimer Pharmaceuticals Inc. (NASDAQ: OPTR) a biopharmaceutical
company, focuses on discovering, developing, and commercializing
anti-infective products. The company develops products that treat
gastrointestinal infections and related diseases. Its two late-stage
anti-infective product candidates include OPT-80, an antibiotic in two
Phase III registration trials for the treatment of Clostridium
difficile-infections/Clostridium difficile-associated disease, the
common nosocomial diarrhea; and Prulifloxacin, an antibiotic in two
Phase III trials for the treatment of infectious diarrhea in travelers,
a community-acquired infection, which is caused by a range of bacteria.
It also develops OPT-1068/CEM-101, a pre-clinical antibiotic against
respiratory tract infections; an OPopS drug discovery platform;
OPT-822, a carbohydrate-based immunostimulant therapy for the treatment
of metastatic breast cancer that completed phase I trials; and OPT-88
as a disease-modifying intra-articular and as a therapy for
osteoarthritis. The company has a collaborative research and
development, and license agreement with Cempra Pharmaceuticals, Inc. to
discover, develop, and commercialize drugs based on macrolide and
ketolide compounds. Optimer Pharmaceuticals was founded 1998 and is
headquartered in San Diego, California. With 29.7 million shares
outstanding and 1.36 million shares declared short as of September
2008, the failure to deliver in shares of OPTR has not been resolved
and a buy-in is imminent. According to quarterly data provided by the
SEC, there were still 286,745 shares of OPTR that were
failing-to-deliver as of February 14, 2007.
Global Med Technologies Inc. (OTCBB: GLOB) designs, develops, markets,
and supports information management software products for blood banks,
hospitals, centralized transfusion centers, and other health care
related facilities in the United States, Africa, Canada, and the
Caribbean. Its products include SafeTrace, which is used to assist
community blood centers, hospitals, plasma centers, and outpatient
clinics for the collection and management of blood and blood products;
SafeTrace Tx, a transfusion management information system designed for
hospitals and centralized transfusion centers to enable the quality of
blood transfused into patient-recipients; and ElDorado Donor, a blood
management software application designed to provide the information
system needs of blood banks and donor centers. The company, through its
subsidiary, PeopleMed.com, Inc., (PeopleMed) develops a software
application designed to provide HMO providers and other third party
payers access to clinical information for chronic disease patients.
PeopleMed supports chronic disease management as an application service
provider and its system uses the Internet to co-ordinate sources of
information and users of a patient's clinical information, including
laboratory, pharmacy, primary and specialty care providers, claims, and
medical records. Global Med Technologies also involves in licensing
software; the provision of maintenance, consulting, and support
services; and in the resale of software obtained from vendors. The
company was founded in 1989 and is based in Lakewood, Colorado. With
30.45 million shares outstanding and 40,600 shares declared short as of
September 2008, the failure to deliver in shares of GLOB has not been
resolved and a buy-in is imminent. According to quarterly data provided
by the SEC, there were still 725,297 shares of GLOB that were
failing-to-deliver as of January 10, 2008.
Ampex Corp. (OTC: AMPXQ) together with its subsidiaries, engages in the
development and licensing of visual information technology products.
The company operates in two segments, Recorders and Licensing. The
Recorders segment primarily engages in the sale and service of data
acquisition and instrumentation recorders that record data and images
rather than computer information; and mass data storage products
consisting of 19-millimeter scanning recorders and robotic library
systems, as well as related tape and after-market parts. The Licensing
segment involves in the licensing of its intellectual property to
manufacturers of consumer digital video products. Ampex Corporation
also holds patents and patent applications covering digital
image-processing, data compression, and recording technologies. In
addition, it develops and incorporates technology in the design and
manufacture of instrumentation recorders primarily for use in defense
applications to gather digital images and other data from aircraft,
satellites, and submarines, as well as for in flight and sensor test
applications. The company distributes its products directly through its
internal sales force, as well as through independent value-added
resellers. Ampex Corporation sells its products and services in the
United States, Europe, Africa, the Middle East, and Japan. Ampex
Corporation was founded in 1944 and is headquartered in Redwood City,
California. On March 30, 2008, Ampex Corp., along with its affiliates,
filed a voluntary petition for reorganization under Chapter 11 in the
US Bankruptcy Court for the Southern District of New York. With 3.90
million shares outstanding and 160,500 shares declared short as of
September 2008, the failure to deliver in shares of AMPXQ has not been
resolved and a buy-in is imminent. According to quarterly data provided
by the SEC, there were still 94,566 shares of AMPXQ that were
failing-to-deliver as of May 21, 2008.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of
publicly traded US companies fight naked short selling. Naked short
selling is the illegal act of short selling a stock when no affirmative
determination has been made to locate shares of the stock to
hypothecate in connection with the short sale. Buyins.net has built a
proprietary database that uses Threshold list feeds from NASDAQ, AMEX
and NYSE to generate detailed and useful information to combat the
naked short selling problem. For the first time, actual trade by trade
data is available to the public that shows the attempted size, actual
size, price and average value of short sales in stocks that have been
shorted and naked shorted. This information is valuable in determining
the precise point at which short sellers go out-of-the-money and start
losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and
publishes a proprietary SqueezeTrigger for each stock that has been
shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database
of nearly 2,150,000,000 short sale transactions goes back to January 1,
2005, and calculates the exact price at which the Total Short Interest
is short in each stock. This data was never before available prior to
January 1, 2005, because the Self Regulatory Organizations (primary
exchanges) guarded it aggressively. After the SEC passed Regulation
SHO, exchanges were forced to allow data processors like Buyins.net to
access the data.
The SqueezeTrigger database collects individual short trade data on
over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on
nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows
by approximately 50,000,000 short sale transactions and provides
investors with the knowledge necessary to time when to buy and sell
stocks with outstanding short positions. By tracking the size and price
of each month's short transactions, BUYINS.NET provides institutions,
traders, analysts, journalists and individual investors the exact price
point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information
believed to be reliable. The information contained herein is not
guaranteed by BUYINS.NET to be accurate, and should not be considered
to be all-inclusive. The companies that are discussed in this opinion
have not approved the statements made in this opinion. This opinion
contains forward-looking statements that involve risks and
uncertainties. This material is for informational purposes only and
should not be construed as an offer or solicitation of an offer to buy
or sell securities. BUYINS.NET is not a licensed broker, broker dealer,
market maker, investment banker, investment advisor, analyst or
underwriter. Please consult a broker before purchasing or selling any
securities viewed on or mentioned herein. BUYINS.NET may receive
compensation in cash or shares from independent third parties or from
the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have
bought or may buy the shares discussed in this opinion and may profit
in the event those shares rise in value. Market commentary provided by
Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not
and will not offer any opinion as to when others should sell; each
investor must make that decision based on his or her judgment of the
market.
This release contains "forward-looking statements" within the meaning
of Section 27A of the Securities Act of 1933, as amended, and Section
21E the Securities Exchange Act of 1934, as amended and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
"Forward-looking statements" describe future expectations, plans,
results, or strategies and are generally preceded by words such as
"may", "future", "plan" or "planned", "will" or "should", "expected,"
"anticipates", "draft", "eventually" or "projected". You are cautioned
that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results
to differ materially from those projected in the forward-looking
statements, including the risks that actual results may differ
materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a companies'
annual report on Form 10-K or 10-KSB and other filings made by such
company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking
statements included herein, and not place undue reliance on such
statements. The forward-looking statements in this release are made as
of the date hereof and BUYINS.NET undertakes no obligation to update
such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET
Tel: +1 800 715 9999
e-mail: Tom@buyins.net
WWW: http://www.buyins.net
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2008 M2 Communications Ltd.
[ Back To TMCnet.com's Homepage ]
|
INDUSTRIES
Activate Email 
Find Solutions for Enterprises, SMBs & Service Providers at the INTERNET TELEPHONY Conference and EXPO East, January 20-22, 2010. Miami, FL.
